| Rheumatoid Arthritis
Hadlima vs Vimovo
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Hadlima vs Vimovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimovo has a higher rate of injection site reactions vs Hadlima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimovo but not Hadlima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hadlima
Vimovo
At A Glance
SC injection
Every other week
TNF-alpha blocker
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Juvenile arthritis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Contraindications
—
- Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Concomitant use of rilpivirine-containing products
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Pharmacology
TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hadlima
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Vimovo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
UnitedHealthcare
Hadlima
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Vimovo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hadlima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vimovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hadlima.
No savings programs available for Vimovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HadlimaView full Hadlima profile
VimovoView full Vimovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.